Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing-Reference-Cited by-同舟云学术

Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing

Published:2024-03 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Rezqallah Alejandra¹^ORCID,Torres-Esquius Sara¹^ORCID,Llop-Guevara Alba²^ORCID,Cruellas Mara³,Martinez María T.⁴^ORCID,Romey Marcel⁵,Denkert Carsten⁵^ORCID,Serra Violeta²^ORCID,Chirivella Isabel⁴,Balmaña Judith¹³^ORCID

Affiliation:

1. Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

2. Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

3. Medical Oncology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain

4. Medical Oncology Department, INCLIVA Biomedical Research Institute, Hospital Clínico de València, University of Valencia, Valencia, Spain

5. Institute of Pathology, Universitätsklinikum Marburg, Marburg, Germany

Abstract

Homologous recombination proficiency in patients with breast cancer despite germline PALB2/RAD51C pathogenic variants.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00446

Reference14 articles.

1. A Population-Based Study of Genes Previously Implicated in Breast Cancer

2. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

3. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality

4. Molecular Pathways: Exploiting Tumor-Specific Molecular Defects in DNA Repair Pathways for Precision Cancer Therapy

5. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation